De novo lymphoid blastic phase chronic myeloid leukemia: report and contemporary discussion.
BCR-ABL
Tyrosine kinase inhibitor
blastic phase CML
blinatumomab
ponatinib
sudden blastic transformation
Journal
Hematology (Amsterdam, Netherlands)
ISSN: 1607-8454
Titre abrégé: Hematology
Pays: England
ID NLM: 9708388
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
entrez:
30
11
2022
pubmed:
1
12
2022
medline:
2
12
2022
Statut:
ppublish
Résumé
We herein describe two cases of de novo lymphoid blastic transformation in patients with no history of chronic-phase chronic myeloid leukemia (CP-CML), both of whom were labeled initially as Philadelphia positive B-Acute Lymphoblastic Leukemia (B-ALL). The first patient was an 18-year-old male who presented with subjective fever, intentional weight loss, generalized fatigue, and headache. Investigations showed leukocytosis (312 × 10^3/ul), thrombocytopenia and anemia. Flowcytometry was consistent with B-ALL, with aberrant expression of CD13 and CD33. He was found to be positive for De novo lymphoid blastic-phase CML can therefore be difficult to differentiate from Philadelphia positive B-ALL due to their overlapping clinical and laboratory picture, implying the need to do myeloid compartment evaluation at the time of diagnosis. With recent progress in the treatment of Philadelphia positive B-ALL, including the role of transplant with the use of novel agents, a better characterization of this disease entity in retrospective and prospective trials is warranted.
Identifiants
pubmed: 36448578
doi: 10.1080/16078454.2022.2150386
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM